Cell line · CVCL_1384
Papers101
1 to 20 of 101
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Integrative Assessment of Teucrium Extracts: Phytochemical Profile, Nutritional-Mineral Composition, Biological Activities, and Toxicological Assessment In Vitro and In Vivo. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A self-amplifying nerve-fibroblast circuit drives colorectal cancer progression. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ASCC3 promotes chemosensitivity in colorectal cancer cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. | ACS Appl Bio Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. | Signal Transduct Target Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting a Glutamic Acid in PDEδ with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. | J Med Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Pivotal Role of GR-CAR Pathway in Fetal Programming of Hepatic Cytochrome P450 3A Alteration in Adulthood. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation. | J Nanobiotechnology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis. | Cancer Drug Resist | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer. | Ann Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of PXR Antagonist MI891 and PXR Degrader MI1013 and Their Roles in Hepatic Gene Regulation. | J Med Chem | 2025 | Its Methods give the RRID and name the line | PubMed | |
| XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1384/papers